BRACE Award Venture Competition

All submitted applications will be reviewed and screened by the Selection Committee based on the quality of applications. Semi-finalists will be chosen and invited to compete in front of a Judging Committee to select finalists who will be recognized and awarded honorariums and certificates.

An Investment Committee will conduct detailed due diligence research on the finalists to determine whether an investment will be made based on the technology platform merits, cancer patient impact, and potential for return on investment. The company that passes the due diligence process will receive up to $600,000 in investment from AIM-HI, AFCR and co-investors.

Eligibility Criteria

• Early-stage oncology companies worldwide seeking pre-seed, seed, and Series A investments are eligible to apply.
• The applying company must have technology ownership in place, and its technology should be able to address cancers prevalent in Asian populations.

For more information, visit AIM-HI Accelerator Fund.